Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galapagos ADR Representing Ord Shs GLPG

Healthcare Biotechnology
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of... see more

Recent & Breaking News (NDAQ:GLPG)

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

GlobeNewswire November 5, 2017

Galapagos moving forward in CF programs at NACFC 2017

GlobeNewswire November 2, 2017

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

GlobeNewswire October 26, 2017

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

GlobeNewswire September 27, 2017

Galapagos increases share capital through warrant exercises

GlobeNewswire September 21, 2017

Morgan Stanley Expects Galapagos Shares To Rise 10%

Benzinga.com  August 10, 2017

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

GlobeNewswire August 9, 2017

Solid financials support R&D progress

GlobeNewswire July 27, 2017

Servier licenses GLPG1972 in osteoarthritis from Galapagos

GlobeNewswire July 27, 2017

Galapagos increases share capital through warrant exercises

GlobeNewswire June 20, 2017

12 Biggest Mid-Day Losers For Tuesday

Benzinga.com  June 20, 2017

Galapagos' R&D Update 2017: rapidly advancing our product candidates

GlobeNewswire June 20, 2017

Galapagos creates new warrant plan

GlobeNewswire May 17, 2017

Seven abstracts on filgotinib accepted by EULAR 2017

GlobeNewswire May 15, 2017

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

GlobeNewswire May 7, 2017

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

GlobeNewswire April 29, 2017

Galapagos reports first quarter 2017 results

GlobeNewswire April 27, 2017

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

GlobeNewswire April 25, 2017

Galapagos announces capital increase

GlobeNewswire April 21, 2017

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

GlobeNewswire April 21, 2017